Euroapi S.A./€EAPI
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Euroapi S.A.
Euroapi S.A. operates in the pharmaceutical industry, specializing in the development, production, and marketing of active pharmaceutical ingredients (APIs). The company provides an extensive range of complex chemical molecules, including pain management and anesthetics, anti-infectives, and endocrine therapy solutions. Headquartered in Paris, France, Euroapi serves global markets, emphasizing high standards in quality and compliance. The company leverages long-standing expertise and technical capabilities, distinguishing itself with a broad product portfolio and investment in research and development to support innovation and meet diverse customer needs.
Ticker
€EAPI
Sector
Primary listing
PAR
Employees
3,187
Headquarters
Website
Euroapi S.A. Metrics
BasicAdvanced
€313M
-
-€1.31
0.69
-
Price and volume
Market cap
€313M
Beta
0.69
52-week high
€4.46
52-week low
€2.26
Average daily volume
5.4K
Financial strength
Current ratio
2.531
Quick ratio
0.598
Long term debt to equity
1.479
Total debt to equity
7.174
Interest coverage (TTM)
-1.57%
Profitability
EBITDA (TTM)
34.1
Gross margin (TTM)
13.71%
Net profit margin (TTM)
-14.08%
Operating margin (TTM)
-2.00%
Effective tax rate (TTM)
2.97%
Revenue per employee (TTM)
€280,000
Management effectiveness
Return on assets (TTM)
-0.68%
Return on equity (TTM)
-13.49%
Valuation
Price to revenue (TTM)
0.351
Price to book
0.42
Price to tangible book (TTM)
0.34
Price to free cash flow (TTM)
-42.489
Free cash flow yield (TTM)
-2.35%
Free cash flow per share (TTM)
-0.077
Growth
Revenue change (TTM)
-9.11%
Earnings per share change (TTM)
-56.99%
3-year revenue growth (CAGR)
-2.21%
3-year earnings per share growth (CAGR)
132.46%
Bulls say / Bears say
EBITDA turned positive at €5.0 million in H1 2025 versus €(1.4) million in the prior period, demonstrating a clear operational turnaround driven by effective cost management (GlobeNewswire).
The net cash position improved to €1.1 million at June 30, 2025, bolstering liquidity and reducing reliance on external financing (GlobeNewswire).
EUROAPI secured up to €140 million in public aid from the French government under the IPCEI Med4Cure project, strengthening its R&D funding and growth investment capacity (GlobeNewswire).
Net sales in H1 2025 fell 8.2% year-on-year to €412.1 million, and full-year 2025 net sales are now expected to decline in the low single digits, underscoring persistent top-line weakness (Euronext).
EUROAPI’s Core EBITDA margin contracted to 9.6% in H1 2025 from 10.6% a year earlier, indicating ongoing margin pressure despite cost control measures (Euronext).
Sales to Sanofi plunged 24.4% to €123.9 million in H1 2025, highlighting significant customer concentration risk and vulnerability to demand shifts from its largest client (EuroAPI).
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Euroapi S.A. stock?
Euroapi S.A. (EAPI) has a market cap of €313M as of October 06, 2025.
What is the P/E ratio for Euroapi S.A. stock?
The price to earnings (P/E) ratio for Euroapi S.A. (EAPI) stock is 0 as of October 06, 2025.
Does Euroapi S.A. stock pay dividends?
No, Euroapi S.A. (EAPI) stock does not pay dividends to its shareholders as of October 06, 2025.
When is the next Euroapi S.A. dividend payment date?
Euroapi S.A. (EAPI) stock does not pay dividends to its shareholders.
What is the beta indicator for Euroapi S.A.?
Euroapi S.A. (EAPI) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.